Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients

Journal of Biological Regulators and Homeostatic Agents

Volumn 14, Issue 3, 2001, Pages 200-203

  Brivio, F ^a   Lissoni, P ^a   Gilardi, R ^a   Ferrante, R ^a   Vigore, L ^a   Curzi, L ^a   Uggeri, F ^a   Nespoli, A ^a   Fumagalli, L ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b Chiron Company   (Italy)

Author keywords

Dendritic cells; Immunosuppression; Immunotherapy; Interleukin 2

Indexed keywords

GLYCOPROTEIN P 15095; INTERLEUKIN 2; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURGERY; CELL COUNT; CELL MATURATION; CIRCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; EVALUATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MOLECULAR RECOGNITION; NEOPLASM; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PROGNOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

EID: 0035066719     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-86.
2. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996; 156: 2918-26.
3. Peters J, Gieseler R, Thiele B, Steinbach F. Dendritic cells: from ontogenic orphans to myelomonocytic descendants. Immunol Today 1996; 17: 277-8.
4. Di Nicola A, Anichini A, Mortarini R, et al. Human dendritic cells: natural adjuvants in antitumor immunotherapy. Cyt Cel Mol Ther 1998; 4: 265-73.
5. Banks RE, Patel PM, Selby PJ. Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 1995; 71: 655-9.
6. Ardizzoia A, Lissoni P, Brivio F, et al. Tumor necrosis factor in solid tumors: increased blood levels in the metasta-tic disease. J Biol Regul Homeost Agents 1992; 6: 103-7.
7. Katsumata N, Eguchi K, Fukuda M, et al. Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res 1996; 2: 553-9.
8. Lissoni P, Barni S, Rovelli F, et al. Correlation of serum interleukin-2 levels, soluble interleukin-2 receptors and T lymphocye subsets in cancer patients. Tumori 1990; 76: 14-7.
9. Akiyoshy T, Koba F, Arinaga S, et al. Impaired production of interleukin-2 after surgery. Clin Exp Immunol 1985; 59: 45-9.
10. Lissoni P, Mengo S, Mandalà M, et al. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variation with surgery and immunotherapy. J Biol Regul Homeost Agents 1998; 12: 38-41.
11. Bancewicz J, Aileen CG, Lindop G. The immunosuppressive effect of surgery. Br J Surg 1973; 60: 314-8.
12. Uchida A, Kolb R, Micksche M. Generation of suppressor cells for natural killer activity in cancer patients after surgery. J Natl Cancer Inst 1982; 68: 735-9.
13. Lazarou SA, Barbul A, Wasserkrug HL, Efron G. The wound is a possible source of post-traumatic immunosuppression. Arch Surg 1989; 124: 1429-31.
14. Brivio F, Lissoni P, Tisi E, et al. Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients. Oncology 1992; 49: 215-8.
15. Nichols PH, Ramsden CW, Ward U, Sedman PC, Primrose JN. Perioperative immunotherapy with recombinat interleukin-2 in patients undergoing surgery for colorectal cancer. Cancer Res 1992; 52: 5765-9.
16. Brivio F, Lissoni P, Gilardi R, et al. Surgery-induced decline in circulating dendritic cells in operable cancer patients. Hepatogastroenterol (in press).
17. O'Doherty U, Peng M, Gezelter S, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994; 82: 487-93.
18. Whittington R, Faulds D. Interleukin-2. Drugs 1993; 46: 446-514.
19. Lotze MT, Hellerstedt B, Stolinski L, et al. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J Sci Am 1997; 3 (suppl): S104-14.